Nothing Special   »   [go: up one dir, main page]

ATE452147T1 - Antikörper mit korrigierten cdr - Google Patents

Antikörper mit korrigierten cdr

Info

Publication number
ATE452147T1
ATE452147T1 AT05723312T AT05723312T ATE452147T1 AT E452147 T1 ATE452147 T1 AT E452147T1 AT 05723312 T AT05723312 T AT 05723312T AT 05723312 T AT05723312 T AT 05723312T AT E452147 T1 ATE452147 T1 AT E452147T1
Authority
AT
Austria
Prior art keywords
antibodies
cdr
corrected
selection
present application
Prior art date
Application number
AT05723312T
Other languages
English (en)
Inventor
Mark S Dennis
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE452147(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE452147T1 publication Critical patent/ATE452147T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05723312T 2004-02-19 2005-02-18 Antikörper mit korrigierten cdr ATE452147T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54584004P 2004-02-19 2004-02-19
PCT/US2005/005270 WO2005080432A2 (en) 2004-02-19 2005-02-18 Cdr-repaired antibodies

Publications (1)

Publication Number Publication Date
ATE452147T1 true ATE452147T1 (de) 2010-01-15

Family

ID=34886204

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05723312T ATE452147T1 (de) 2004-02-19 2005-02-18 Antikörper mit korrigierten cdr

Country Status (9)

Country Link
US (2) US20060122377A1 (de)
EP (3) EP1716181B1 (de)
AT (1) ATE452147T1 (de)
AU (1) AU2005214382B2 (de)
CA (1) CA2555820C (de)
DE (1) DE602005018325D1 (de)
DK (1) DK1716181T3 (de)
ES (1) ES2337473T3 (de)
WO (1) WO2005080432A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1664115A2 (de) * 2003-08-01 2006-06-07 Genentech, Inc. Antikörper cdr polypeptid-sequenzen mit limitierter diversität
DK2990422T3 (en) 2004-09-03 2018-09-17 Genentech Inc HUMANIZED ANTI-BETA7 ANTAGONISTS AND APPLICATIONS THEREOF
EP1869084A2 (de) 2005-03-04 2007-12-26 Biogen Idec MA Inc. Verfahren zur humanisierung der variablen regionen von immunoglobulin durch rationale modifikation der komplementaritätsbestimmenden reste
PE20110071A1 (es) 2005-05-19 2011-01-31 Centocor Inc Anticuerpos anti-mcp-1, composiciones y metodos
RU2423382C1 (ru) 2005-06-20 2011-07-10 Дженентек, Инк. Композиции и способы диагностики и лечения опухоли
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1957531B1 (de) * 2005-11-07 2016-04-13 Genentech, Inc. Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
EP1973951A2 (de) * 2005-12-02 2008-10-01 Genentech, Inc. Bindende polypeptide mit eingeschränkten diversitätssequenzen
WO2007093042A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US7749772B1 (en) 2006-06-29 2010-07-06 Varian, Inc. Antibody and immunoassays for determining the presence of Δ9-Tetrahydrocannabinol
WO2008106116A2 (en) * 2007-02-27 2008-09-04 Genentech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
MX2009010092A (es) 2007-03-22 2010-02-09 Genentech Inc Anticuerpos anti ige apoptoticos.
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
AU2008304756B8 (en) 2007-09-26 2015-02-12 Chugai Seiyaku Kabushiki Kaisha Anti-IL-6 receptor antibody
MX2010010085A (es) 2008-03-14 2011-03-29 Biocon Ltd Un anticuerpo monoclonal y el metodo para su uso.
US20170204191A1 (en) 2008-10-06 2017-07-20 Cynthia C. Bamdad Muc1* antibodies
CN103772500A (zh) 2009-05-08 2014-05-07 霍夫曼-拉罗奇有限公司 人源化抗egfl7抗体及其使用方法
CN104379741B (zh) 2012-04-23 2021-07-20 基因先端领域株式会社 抗人cd69抗体及其用于医疗目的的用途
JP6268173B2 (ja) 2012-07-19 2018-01-24 第一三共株式会社 抗Ｓｉｇｌｅｃ−１５抗体
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
PL220297B1 (pl) * 2012-11-07 2015-10-30 Wrocławskie Ct Badań Eit & Spółka Z Ograniczoną Odpowiedzialności& Epitop i jego zastosowanie
AU2013342779B2 (en) 2012-11-09 2019-09-26 Genefrontier Corporation Anti-ADAM28 antibody for treating cancer
ES2728854T3 (es) 2013-02-06 2019-10-29 Univ Yokohama City Anticuerpo anti-semaforina 3A y tratamiento de enfermedad de Alzheimer y enfermedades inmunitarias inflamatorias usando el mismo
EP3936148A1 (de) 2013-07-23 2022-01-12 Biocon Limited Verwendung eines cd6-bindungspartners und verfahren damit
AU2014335251B2 (en) 2013-10-15 2020-04-30 Genefrontier Corporation Human antibody against aggrecanase-type ADAMTS species for therapeutics of aggrecanase-related diseases
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
CA2976089A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CN105281984A (zh) * 2015-11-27 2016-01-27 上海斐讯数据通信技术有限公司 一种抓取和过滤报文的虚拟终端和方法
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
DK3529274T3 (da) 2016-10-21 2024-06-17 Biocon Ltd Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
EP3728323A4 (de) 2017-12-19 2022-01-26 Surrozen Operating, Inc. Anti-frizzled-antikörper und verfahren zur verwendung
EP3732201A4 (de) 2017-12-19 2022-04-20 Surrozen Operating, Inc. Wnt-surrogatmoleküle und deren verwendungen
CN112567039A (zh) 2018-08-07 2021-03-26 大日本住友制药株式会社 阿尔茨海默氏病的诊断药物和诊断方法
EP4101465A4 (de) 2020-02-05 2024-03-06 Sumitomo Pharma Co., Ltd. Bestimmungsmittel und bestimmungsverfahren für tauopathie und demenz-assoziierte erkrankungen
US20240190992A1 (en) 2021-04-05 2024-06-13 University Public Corporation Osaka Antibody against pancreatic cancer stem cells

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432A (en) 1848-02-01 Improvement in machinery for knitting
US18A (en) 1836-08-31 Thomas blanchard
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
EP0266032A1 (de) 1986-08-29 1988-05-04 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
JPS649774A (en) 1987-07-02 1989-01-13 Fujitsu Ltd Thermal transfer printing method
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
ES2075016T3 (es) 1988-08-23 1995-10-01 Dana Farber Cancer Inst Inc La subunidad alfa del receptor de adherencia a leucocitos lfa-1.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH02189420A (ja) 1989-01-17 1990-07-25 Omron Tateisi Electron Co ディジタルパネルメータ
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
GB9100816D0 (en) 1991-01-15 1991-02-27 Unilever Plc Cosmetic composition
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0940468A1 (de) * 1991-06-14 1999-09-08 Genentech, Inc. Änderliches Gebiet einer humanisierter Antikörper
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US6107059A (en) * 1992-04-29 2000-08-22 Affymax Technologies N.V. Peptide library and screening method
EP0656064B1 (de) 1992-08-17 1997-03-05 Genentech, Inc. Bispezifische immunoadhesine
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
KR100362340B1 (ko) 1993-09-07 2003-02-26 스미스클라인비이참피이엘시이 인터로이킨-4(il4)매개된질환의치료에유용한재조합il4항체
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
DE122004000047I1 (de) 1996-11-27 2005-04-21 Genentech Inc Humanisierte anti-koerper gegen cd11a.
DK2301580T3 (da) 1997-04-07 2012-05-14 Genentech Inc Beholder med anti-VEGF-antistoffer
ATE349470T1 (de) 1997-04-07 2007-01-15 Genentech Inc Anti-vefg antibodies
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
PT1265928E (pt) 2000-01-27 2010-09-30 Medimmune Llc Anticorpos neutralizantes com afinidade ultra-elevada
CA2403425C (en) 2000-04-11 2013-08-27 Genentech, Inc. Multivalent antibodies and uses therefor
EP2180044A1 (de) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antikörperglykosylierungsvarianten mit gesteigerter antikörperabhängiger zellulärer Zytotoxizität
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
DK1501856T3 (da) 2002-04-10 2013-03-25 Genentech Inc Anti-HER2 antistofvarianter
EP1551453A4 (de) 2002-06-17 2007-04-25 Us Gov Health & Human Serv Spezifitätsgrafting eines mäuseantikörpers auf ein menschliches gerüst
AU2003248744C1 (en) * 2002-06-28 2009-12-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized anti-TAG-72 CC49 for diagnosis and therapy of human tumors
JP2006512895A (ja) * 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
HUE049161T2 (hu) 2003-12-23 2020-09-28 Genentech Inc Új anti-IL13 antitestek és alkalmazásaik
CA2619654A1 (en) 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions

Also Published As

Publication number Publication date
ES2337473T3 (es) 2010-04-26
AU2005214382A1 (en) 2005-09-01
US20110237779A1 (en) 2011-09-29
WO2005080432A3 (en) 2006-02-16
EP2168986A3 (de) 2010-07-28
CA2555820A1 (en) 2005-09-01
AU2005214382B2 (en) 2011-08-04
CA2555820C (en) 2016-01-19
DK1716181T3 (da) 2010-03-01
EP1716181B1 (de) 2009-12-16
EP3653641A1 (de) 2020-05-20
US8580928B2 (en) 2013-11-12
EP1716181A2 (de) 2006-11-02
US20060122377A1 (en) 2006-06-08
EP2168986A2 (de) 2010-03-31
WO2005080432A2 (en) 2005-09-01
DE602005018325D1 (de) 2010-01-28

Similar Documents

Publication Publication Date Title
ATE452147T1 (de) Antikörper mit korrigierten cdr
ATE434626T1 (de) Humanisierter antikörper gegen cd4 mit immunsuppressiven merkmalen
TW200616662A (en) Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
TW200700081A (en) Anti-ctla-4 antibody compositions
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
NZ602294A (en) Monoclonal antibodies against c-met
CR20150102A (es) Anticuerpos que se unen a il-4 y/o il-13 (divisional 2)
CR20110577A (es) Proteínas de unión a il-1
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
IL180152A0 (en) Chimeric and humanised monoclonal antibodies against inteleukin-13
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
IL191217A (en) Anti-17 mantle monoclonal antibody
ATE382683T1 (de) Monoklonales antikörper gegen das hcv kernantigen
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
RS53263B (en) CD19 OPTIMIZED ANTIBODY
WO2009112245A9 (en) Antibody against the csf-1 r
PA8650001A1 (es) Formulaciones de anticuerpo
RS52860B (en) ANTI-ILT7 ANTITELO
MX2008002161A (es) Anticuerpos quimericos con regiones de primate del nuevo mundo.
NZ595863A (en) Antibodies to egfl7 and methods for their use
NZ594668A (en) Humanised antibodies with anti-tumour activity
WO2008052108A3 (en) Methods for use in human-adapting monoclonal antibodies
WO2008081331A3 (en) Enhancing the level of antibody expression by framework re-engineering

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties